SCHEMBL2020543

SCHEMBL2020543

O=c1[nH][nH]c(-c2ccccc2)c1-c1cn2c3c(cccc13)CCC2

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ OPA1 O60313 1/20 0.42
▸ EIF5B O60841 1/20 0.42
▸ MET P08581 1/20 0.42
▸ HMOX2 P30519 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2C P28335 1/20 0.42
▸ GSK3B P49841 2/20 0.40
▸ MTNR1A P48039 6/20 0.38
▸ MTNR1B P49286 6/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CDK4 P11802 1/20 0.35
▸ CCND1 P24385 1/20 0.35
▸ GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017958 0.90 HPGD (0.40) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2020158 0.90 OPA1 (0.40) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2017097 0.88 OPA1 (0.39) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2018145 0.87 OPA1 (0.39) HSD17B10KDM4ELMNAOPA1EIF5B
SCHEMBL2015557 0.87 OPA1 (0.41) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2015795 0.87 HTR2A (0.43) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2016690 0.86 GSK3B (0.40) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2018580 0.83 OPA1 (0.53) HSD17B10LMNAOPA1EIF5BMET
SCHEMBL12631647 0.82 KDM4E (0.40) HSD17B10KDM4ELMNACYP1A2OPA1
SCHEMBL2021104 0.81 CDK4 (0.39) HSD17B10KDM4EOPA1EIF5BMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 — — US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 — — US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 — — WO disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 — — WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 — — US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 HSD17B10 974/4885KDM4E 1439/4885LMNA 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback